Stock 6848 RBC BIOSCIENCE CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up

Financials RBC Bioscience Corporation

Equities

6848

TW0006848005

Medical Equipment, Supplies & Distribution

End-of-day quote Taipei Exchange
Other stock markets
 03:30:00 28/06/2024 am IST 		5-day change 1st Jan Change
17.5 TWD +2.34% Intraday chart for RBC Bioscience Corporation -1.13% +8.02%
24/04 RBC Bioscience Corporation Reports Earnings Results for the Full Year Ended December 31, 2023 CI
2023 RBC Bioscience Corporation Reports Earnings Results for the Half Year Ended June 30, 2023 CI

Valuation

Fiscal Period: December 2021 2022 2023
Capitalization 1 459.5 205.7 210.2
Enterprise Value (EV) 1 873 611.5 616.7
P/E ratio 15.2 x 54.7 x 33.1 x
Yield 2.57% 7.07% 2.72%
Capitalization / Revenue 1.83 x 1.18 x 1.22 x
EV / Revenue 3.48 x 3.52 x 3.58 x
EV / EBITDA 14.2 x 24.4 x 19.4 x
EV / FCF -18,94,273 x 3,06,90,738 x 20,93,52,080 x
FCF Yield -0% 0% 0%
Price to Book 1.79 x 0.83 x 0.87 x
Nbr of stocks (in thousands) 12,976 12,976 12,976
Reference price 2 35.41 15.85 16.20
Announcement Date 28/04/22 27/04/23 24/04/24
1TWD in Million2TWD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 126 161.7 575.2 251.2 173.9 172.5
EBITDA 1 20.09 24.85 195.5 61.47 25.04 31.86
EBIT 1 14.11 19.52 187.8 48.61 7.75 14.54
Operating Margin 11.19% 12.07% 32.65% 19.35% 4.46% 8.43%
Earnings before Tax (EBT) 1 17.1 18.03 177.3 35.95 4.916 7.873
Net income 1 13.7 14.46 141.9 28.73 3.778 6.43
Net margin 10.87% 8.94% 24.67% 11.44% 2.17% 3.73%
EPS 2 1.201 1.253 11.44 2.327 0.2900 0.4900
Free Cash Flow - 25.72 50.35 -460.8 19.92 2.946
FCF margin - 15.91% 8.75% -183.47% 11.46% 1.71%
FCF Conversion (EBITDA) - 103.48% 25.75% - 79.58% 9.25%
FCF Conversion (Net income) - 177.91% 35.49% - 527.37% 45.81%
Dividend per Share - 1.179 5.065 0.9091 1.120 0.4400
Announcement Date 19/07/21 19/07/21 19/07/21 28/04/22 27/04/23 24/04/24
1TWD in Million2TWD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 25.4 24.4 - 414 406 406
Net Cash position 1 - - 3.47 - - -
Leverage (Debt/EBITDA) 1.263 x 0.9825 x - 6.727 x 16.21 x 12.76 x
Free Cash Flow - 25.7 50.4 -461 19.9 2.95
ROE (net income / shareholders' equity) - 16.7% 108% 13.3% 1.49% 2.63%
ROA (Net income/ Total Assets) - 6.64% 32.9% 4.47% 0.59% 1.18%
Assets 1 - 217.6 431.4 643.1 638.9 546.4
Book Value Per Share 2 8.070 7.920 15.80 19.80 19.20 18.60
Cash Flow per Share 2 2.070 3.910 11.20 7.510 5.850 5.020
Capex 1 69.9 9.08 118 450 9.96 4.99
Capex / Sales 55.47% 5.62% 20.59% 179.04% 5.73% 2.9%
Announcement Date 19/07/21 19/07/21 19/07/21 28/04/22 27/04/23 24/04/24
1TWD in Million2TWD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Medical Equipment, Supplies & Distribution

1st Jan change Capi.
RBC BIOSCIENCE CORPORATION Stock RBC Bioscience Corporation
+8.02% 6.99M
ABBOTT LABORATORIES Stock Abbott Laboratories
-5.60% 181B
MEDTRONIC PLC Stock Medtronic plc
-4.45% 101B
BECTON, DICKINSON AND COMPANY Stock Becton, Dickinson and Company
-4.15% 67.54B
DEXCOM, INC. Stock DexCom, Inc.
-8.63% 45.09B
CENCORA, INC. Stock Cencora, Inc.
+9.70% 44.37B
HOYA CORPORATION Stock Hoya Corporation
+6.13% 40.7B
METTLER-TOLEDO INTERNATIONAL, INC. Stock Mettler-Toledo International, Inc.
+15.22% 29.85B
TERUMO CORPORATION Stock Terumo Corporation
+14.80% 24.49B
WEST PHARMACEUTICAL SERVICES, INC. Stock West Pharmaceutical Services, Inc.
-6.46% 23.99B
Other Medical Equipment, Supplies & Distribution
  1. Stock Market
  2. Equities
  3. 6848 Stock
  4. Financials RBC Bioscience Corporation